药明康德(603259.SH)拟认购北海康成股份 研发罕见病药物
药明康德(02359.HK)(603259.SH)公布,公司全资子企业药明基金一期、General Atlantic等8名投资人与北海康成及其他相关方签署优先股认购协议,其中药明基金一期拟认购北海康成新发行约169.21万股优先股股份,认购金额约为2,000.03万美元。
同时,北海康成还将向药明基金一期发行一项未来可认购北海康成股份的认股权证,药明基金一期有权在最高1,000.01万美元的价款范围内认购北海康成优先股股份。
投资完成後,药明康德持有北海康成股份13.11%。北海康成专注於首创罕见病药物的研发,具备多个罕见病药物管线。通过关联交易,公司将进一步完善在罕见病领域的生态圈布局,间接促进罕见病领域的新药研发,令病患早日获益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.